Apart of the extended number of the originally recommended CDC Atlanta CFIDS criteria contained in the questionnaire is there any other laboratory way to diagnose CFIDS?
University of Newcastle research team /Australia/ provide ‘Bioscreen’ tests which show statistical high correlation between CFIDS and the appearance of certain urinary metabolites such as amino-hydroxy-N-methyl-pyrrolidine (CFSUM1), unidentified urinary marker CFSUM2, tyrosine, beta-alainine, acotic acid and succinic acid. The abundances of CFSUM1 and b-alanine were positively correlated with the CFIDS symptom incidence and the ‘core’ of the CFIDS symptoms.
